Trial
NCT03406715
Combination Immunotherapy-Ipilimumab-Nivolumab-Dendritic Cell p53 Vac - Patients With Small Cell Lung Cancer (SCLC)
Phase IITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
H. Lee Moffitt Cancer Center and Research Institute
Collaborators
Bristol-Myers Squibb; MultiVir, Inc.
Condition
Small Cell Lung Cancer
Intervention
Nivolumab
Why stopped
Sponsor closed study
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2023-03-30